Vulvovaginal or vaginal atrophy in postmenopausal women
Ospemifene is considerably more expensive than other products available to treat vulvar and vaginal atrophy. No direct evidence is available to make comparison with currently available products.
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria